All In Biotech

Drug Trial Radar · NCT00077623

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis

Last checked: Nov 20, 2026Latest source record: May 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

572

Actual

Start

Mar 2004

Primary completion

Sep 2005

Study completion Sep 2005

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 13, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

Conditions

  • Anemia

Interventions

  • epoetin alfa or betaDrug

    iv 3 times weekly, as prescribed

  • methoxy polyethylene glycol-epoetin beta (Mircera)Drug

    60, 100 or 180 micrograms sc (starting dose) every 2 weeks

  • methoxy polyethylene glycol-epoetin beta (Mircera)Drug

    60, 100 or 180 micrograms sc (starting dose) every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Hemoglobin Concentration From Baseline to Evaluation PeriodsTime frame: Baseline (Week -4 to Week -1) and Evaluation period (Week 29 to Week 36)

Locations

90 sites in 21 countries. Site status is shown where the registry gives one.

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Los Angeles, California

  • Site not named

    Riverside, California

  • Site not named

    Sacramento, California

  • Site not named

    San Jose, California

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Brooklyn Center, Minnesota

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Toledo, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Morgantown, West Virginia

  • Site not named

    Brussels, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Hasselt, Belgium

  • Site not named

    Curitiba, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Brno, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Pilsen, Czechia

  • Site not named

    Odense, Denmark

  • Site not named

    HUS, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Bayonne, France

  • Site not named

    Boulogne, France

  • Site not named

    Cabestany, France

  • Site not named

    Caen, France

  • Site not named

    Limoges, France

  • Site not named

    Nîmes, France

  • Site not named

    Pantin, France

  • Site not named

    Poitiers, France

  • Site not named

    Saint-Germain-en-Laye, France

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.